Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
News|Videos|November 11, 2026
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study
Author(s)Kohei Shitara, MD
Rapid readout: Phase 3 GHOPE-001 shows claudin 18.2 ADC AT extends PFS/OS vs chemo in late-line gastric/GEJ cancer, manageable safety.
Advertisement
A clinical study compared arcotatug tavatecan against standard treatment options for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. The trial's findings revealed that the investigational antibody-drug conjugate significantly improved both progression-free survival and overall survival compared to the control group. Furthermore, patients treated with arcotatug tavatecan experienced durable responses with a manageable safety profile.
Advertisement
Related to this article
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.
Frailty is common among older adults with blood cancers and strongly predicts survival, independent of age.
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pimicotinib for Symptomatic TGCT
2
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
3
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5